Financial Performance - The net profit attributable to shareholders decreased by 63.98% year-on-year, primarily due to an increase in government subsidies compared to the previous year[33]. - The net cash flow from operating activities increased by 56.71% year-on-year, mainly due to an increase in government subsidies received and tax refunds from national preferential policies[34]. - The company plans not to distribute cash dividends or bonus shares, nor to increase capital from reserves[16]. - The company reported a significant decline in pharmaceutical service revenue, leading to an increase in asset impairment provisions[33]. - The net profit attributable to shareholders in the fourth quarter significantly decreased compared to the previous three quarters due to the full impairment provision for R&D projects that could not meet expectations[37]. - The net profit excluding non-recurring gains and losses in the fourth quarter also saw a substantial decline, primarily due to government subsidies received during the quarter[37]. - Government subsidies recognized in the current period amounted to approximately ¥130.05 million, which is a key factor in the financial results[39]. - The total net profit after tax and minority interests for the fourth quarter was approximately ¥111.91 million, reflecting the impact of the aforementioned factors[39]. - The company’s operating revenue for 2022 was ¥3,836,640,799.74, a decrease of 12.98% compared to ¥4,409,035,585.85 in 2021[51]. - The net profit attributable to shareholders for 2022 was ¥191,277,350.92, down 31.29% from ¥278,398,951.02 in 2021[51]. - The net profit after deducting non-recurring gains and losses was ¥79,371,328.72, a decline of 63.98% compared to ¥220,375,153.57 in 2021[51]. - The net cash flow from operating activities increased by 56.71% to ¥472,065,141.66 in 2022, up from ¥301,231,402.96 in 2021[51]. - The total assets at the end of 2022 were ¥12,543,503,416.06, reflecting a 3.11% increase from ¥12,165,124,976.56 at the end of 2021[51]. - The net assets attributable to shareholders increased by 3.24% to ¥8,811,484,555.00 at the end of 2022, compared to ¥8,535,174,993.28 at the end of 2021[51]. - The company reported a basic earnings per share of ¥0.16 for 2022, down 30.43% from ¥0.23 in 2021[51]. - The weighted average return on equity for 2022 was 2.20%, a decrease of 1.08% from 3.28% in 2021[51]. Risk Management - The company has identified various risks in its operations, including R&D underperformance, goodwill impairment, exchange rate fluctuations, international business risks, and safety and environmental risks[5]. - The company has not experienced any substantial risks that could significantly impact its production and operations during the reporting period[5]. - The company emphasizes the importance of understanding the differences between plans, forecasts, and commitments in its future development statements[11]. Research and Development - The company is focusing on R&D projects, including the development of new products such as F-627 and F-652, which are currently under research[43]. - The company aims to leverage innovation to meet unmet clinical needs and enhance international competitiveness in the pharmaceutical sector[85]. - The company will adopt a cooperative and self-research approach for new product development, emphasizing innovation-driven strategies and green manufacturing initiatives[102]. - The company is committed to pursuing high-quality sustainable development by focusing on patient needs and avoiding homogenized competition in drug development[102]. - The company will focus on key traditional Chinese medicine products, enhancing development and academic construction to elevate product academic status and transition to mass branding[95]. - The company aims to strengthen its innovation capabilities in synthetic biology technology through collaboration with research institutions and self-built R&D teams, aligning with global trends[97]. - The company has improved its procurement system for core Chinese medicinal materials and key raw materials, ensuring optimal supplier performance in price, quality, and service[108]. - The company has established a complete independent system for R&D, procurement, production, and sales based on market demand and its actual situation[108]. - The company’s new product development is primarily based on independent R&D, supplemented by collaborations with overseas and domestic research institutions[112]. Market Position and Strategy - The company holds a leading position in the vitamin B5 market, with over 70% of its sales directed to Europe and the United States[69]. - The company plans to continue its market expansion and strategic acquisitions to enhance its competitive position in the pharmaceutical industry[43]. - The company is one of the few domestic firms to submit new drug applications for the same product simultaneously in the US, Europe, and China, indicating strong market positioning[88]. - The company has a high global market share in raw material drugs, with over 70% of Vitamin B5 products sold to Europe and the US, maintaining a leading position[88]. - The company’s sales strategy for the product Aibegesitin α injection mainly involves external authorization, receiving milestone payments and net sales royalties[110]. - The company’s core Chinese medicine products and key chemical drug products are produced based on market sales conditions and product demand plans[108]. Environmental Compliance - The company has established a comprehensive emergency response mechanism for environmental pollution incidents and has conducted multiple drills to enhance emergency handling capabilities[173]. - The company has achieved compliance in all monitored environmental discharge parameters, including wastewater and air emissions, with specific values such as 19.7 mg/L for biochemical oxygen demand and 8.5 mg/m³ for particulate matter[171]. - The company has implemented a "2022 Employee Stock Ownership Plan" to motivate and retain talent, alongside a comprehensive employee benefits system[177]. - The company has made significant investments in pollution control facilities, including a rotary kiln incinerator and a sludge dewatering machine, to ensure compliance with environmental regulations[171]. - The company has maintained transparency in information disclosure, enhancing communication with investors through various channels[176]. - The company has no recorded violations or penalties during the reporting period, indicating a strong compliance record[174]. - The company reported that it continues to meet environmental discharge standards for its operations[191]. - The company has established online monitoring systems for wastewater and air emissions, with data automatically uploaded to environmental authorities, ensuring compliance with national monitoring regulations[198]. - In 2022, all self-monitoring and supervisory monitoring results were compliant, demonstrating the company's effective pollution management capabilities[198]. - The company is actively conducting annual carbon emission audits to guide energy-saving measures across departments, aiming to reduce overall energy consumption[199]. Employee and Governance - The total number of employees is 4,338, with 1,092 in sales, 849 in technical roles, and 178 in finance[145]. - The company has implemented a training program for employees, focusing on various levels and roles to enhance skills and performance[146]. - The company’s governance structure includes various committees that have met multiple times to discuss performance evaluations and compensation plans[143]. - The company has a total of 36 employees with a PhD, 213 with a master's degree, and 1,278 with a bachelor's degree, indicating a strong educational background among staff[145]. - The employee stock ownership plan purchased a total of 7,292,100 shares, accounting for 0.59% of the company's total share capital, at an average price of RMB 10.765 per share, totaling approximately RMB 78.5 million[157]. - The company has implemented a dynamic management approach for its R&D projects, increasing investment in key products[138]. - The company plans to enhance its governance structure and internal control systems to improve operational compliance and investor relations[189].

现场参与地点：安徽省合肥市肥西县桃花镇繁华大道与文山路交口，合肥亿 帆生物制药有限公司一楼会议室。 亿帆医药股份有限公司（以下简称"公司"）于2023年4月15日在巨潮资讯 网上披露了《2022年年度报告》，为了让广大投资者更深入全面地了解公司经营 管理、发展战略、行业前景等情况，公司将举行2022年度业绩说明会，具体安排 如下： 一、说明会时间、地点和形式 股票代码：002019 股票简称：亿帆医药 公告编号：2023-030 亿帆医药股份有限公司 关于举行 2022 年度业绩说明会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要事项提示： 会议时间：2023年6月2日（周五） 13:00-15:00 会议形式：现场参与+网络视频直播 欢迎广大投资者积极参与本次网上说明会。 （问题征集二维码） 召开时间：2023年6月2日（周五）13:00-15:00 召开形式：现场参与+网络视频直播 本次业绩说明会将采用"现场参与+网络视频直播"的方式实现线上线下同 步进行。线下会场设在安徽省合肥市肥西县桃花镇繁华大道与文山路交口，合肥 亿帆生物制药有限公司一 ...

Group 1: Company Overview - The company is Zhejiang Hangzhou Xinfuyuan Pharmaceutical Co., Ltd. with stock code 002019 [1] - The investor relations activity took place on November 6, 2014, in Hefei, Anhui Province [2] Group 2: Investor Relations Activity - The event was categorized as an investor reception day, attended by various securities analysts and fund representatives [2] - Key company representatives included the Chairman, General Manager, Deputy General Manager, CFO, and Secretary of the Board [2] Group 3: Policy and Market Impact - Discussion on the potential impact of the National Development and Reform Commission's proposed drug price management reforms on the company [2][3] - The company does not base its development strategy solely on pricing but aims to strengthen its foundation through product diversification and vertical and horizontal industry development [3] Group 4: Future Development Directions - Future focus will be on the integration of pharmaceutical raw materials and products, with potential expansion into the healthcare industry [3] - Plans for overseas product development include product agency, ownership buyouts, and acquisitions of foreign companies [3] Group 5: Market Trends - Current pricing of calcium pantothenate is at a relatively low level, with future price trends difficult to predict; the company will adapt to market conditions [3]

Group 1: Company Overview - Yifan Xinfu Pharmaceutical Co., Ltd. is actively engaging in investor relations activities to provide insights into its operations and strategic direction [1]. - The company is located in Hefei, Anhui Province, and the meeting took place on May 6, 2015 [1]. Group 2: Industry Position and Strategy - The company is focused on the healthcare industry, with ongoing efforts to adapt to national policies and explore effective collaboration models [2]. - Future development in the pharmaceutical sector is centered around innovation and targeted product acquisitions [2]. Group 3: Product Development and Pricing - Yifan Xinfu aims to strengthen its core business in the pantothenic acid series while also developing biodegradable materials [2]. - The recent price drop of pantothenic acid products is a strategic decision based on market conditions, with the company expressing a willingness to increase market share [2]. - The impact of drug price deregulation is expected to be minimal in the short term, but long-term effects may influence companies relying on individually priced products for profit [2].

Group 1: Price Trends and Market Conditions - The recent global market has seen an upward trend in the prices of vitamin products, including calcium pantothenate (vitamin B5), which was at a low price point in 2015 and is expected to rise [2] - The tightening of domestic environmental regulations may have led to some manufacturers being unable to fully release production capacity, resulting in a market characterized by tight supply and increased production costs [2] - The company anticipates that the price of calcium pantothenate will continue to rise in the future, although the duration and extent of the increase are uncertain and ultimately determined by market conditions [2] Group 2: Production and Capacity - The total production capacity for the company's pantothenic acid series products is 12,000 tons per year [2] - The company will decide on order placements based on market conditions and actual production situations, with prices generally following market trends [2] Group 3: Strategic Development - The company's future strategic focus includes three main areas: pharmaceutical raw materials, drug formulations, and the healthcare sector [2] - The company aims to enhance innovation and promote business integration and upgrading while achieving some success in internationalization through strategies like "going out" and "bringing in" [3] - In developing regions, the company plans to establish local factories to supply domestic products, while in developed regions like Europe and the U.S., it will pursue acquisitions of international pharmaceutical companies to expand its global market presence [3]

Group 1: Product Pricing and Market Trends - The price of calcium pantothenate is expected to rise due to a general upward trend in vitamin product prices globally [2] - In 2015, the price of vitamin B5 (calcium pantothenate) was at a low level, indicating potential for upward movement [2] - Strict domestic environmental regulations may have limited production capacity for some manufacturers, leading to a tight supply and increased production costs [2] - The company's total production capacity for pantothenic acid series products is 12,000 tons per year [2] Group 2: Biodegradable Materials - The company launched a fully biodegradable materials project in 2007, featuring proprietary technology and the first continuous production facility in China with a capacity of 10,000 tons [3] - The biodegradable products have gained recognition from customers in Europe and the United States, and the company is the drafting unit for national standards [3] - The products are primarily exported, but domestic demand is expected to grow as environmental regulations become stricter [3] Group 3: Healthcare Development Strategy - The company aims to establish a hospital management system in Anhui within 3-5 years, starting with the management of county-level hospitals [3] - The strategy includes building high-end hospitals and a national chain for specialized treatments, focusing on chronic disease management [3] - The company has initiated its healthcare business by partnering with top medical institutions in Anhui and successfully managing a county hospital [4] Group 4: Future Business Strategy - The company’s strategic focus post-restructuring includes pharmaceutical raw materials, drug formulations, and healthcare sectors [4] - Plans for domestic integration of product lines and international expansion through local manufacturing in underdeveloped regions and acquisitions in developed markets are outlined [4]

Group 1: Company Overview - Yifan Xinfu Pharmaceutical Co., Ltd. is involved in strategic cooperation with Jianenlong, focusing on innovation and international market strategies [2][3]. - The major shareholder remains unchanged post-transaction, indicating a financial investment completion [3]. Group 2: Core Competencies - Jianenlong's core competencies include advanced technology and a strong management team, with two major platforms for intellectual property protection [3]. - The company has established a cGMP-compliant industrialization factory according to FDA standards and is the first Chinese biotech firm to conduct Phase II clinical trials in the U.S. [3]. Group 3: Financial Insights - Jianenlong has invested over $80 million since its establishment and requires an additional $200 million in the next 2-3 years for future financing [4]. - The G-CSF project, originally developed by Amgen, is expected to generate a market share of $6 billion annually in Europe and the U.S., with long-acting products accounting for 80% of that market [4]. Group 4: Market Potential - The orphan drug project F-652 is projected to reach a market capacity of $1-1.2 billion, benefiting from shorter clinical timelines and faster approval processes [4].

Group 1: Company Performance - The company achieved a revenue of 1.732 billion CNY in the first half of 2016, representing a year-on-year growth of 42.16% [4] - The net profit attributable to shareholders was 364.27 million CNY, with a year-on-year increase of 113.15% [4] - The raw material drug segment showed significant profit growth, contributing to the overall profit increase [4] Group 2: Product and Market Developments - The price of calcium pantothenate is stable and expected to rise slightly in the third quarter, with tight inventory levels [3] - The company acquired a 53.57% stake in Anhui Wanhua Pharmaceutical, primarily to leverage overseas sales channels for vitamin K1 [3] - The company’s agent product, Cefoperazone, showed steady revenue growth in the pharmaceutical formulation segment [5] Group 3: Research and Development - The DHY company's research projects are progressing as planned, with F627 entering international Phase III clinical trials [4] - Other in-development products are also advancing through various clinical stages [4] Group 4: Future Strategy - The company’s future plans focus on integration, innovation, and internationalization [6] - Plans include establishing and acquiring multiple pharmaceutical companies to enhance synergy and resource complementarity [6] - The company aims to enhance R&D capabilities through the introduction of high-tech talent and collaboration [6]

Financial Performance - Revenue for Q3 2022 was ¥959,518,634.11, a decrease of 5.94% year-over-year, and a total revenue of ¥2,728,866,329.74 for the year-to-date, down 19.68% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2022 was ¥42,696,040.25, a decline of 45.00% year-over-year, with year-to-date net profit of ¥203,256,070.64, down 30.10%[3]. - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥24,925,435.23, a decrease of 62.08% year-over-year, and year-to-date was ¥130,283,488.50, down 47.89%[3]. - The company reported a significant decrease in pharmaceutical service revenue, which contributed to the decline in net profit[3]. - The company reported a net profit margin decline due to reduced operating revenue and increased costs, impacting overall profitability[22]. - The total revenue for Q3 2022 was approximately 753.19 million, an increase from 607.22 million in Q3 2021, representing a growth of about 24%[24]. - The net profit for Q3 2022 was approximately 150.26 million, down from 242.33 million in Q3 2021, indicating a decrease of about 38%[24]. - Operating profit for Q3 2022 was approximately 186.75 million, compared to 277.14 million in Q3 2021, reflecting a decline of about 33%[24]. - The basic earnings per share for Q3 2022 was 0.16, compared to 0.24 in Q3 2021, a decline of about 33%[25]. - The total comprehensive income attributable to the parent company's owners for Q3 2022 was approximately 196.35 million, compared to 204.24 million in Q3 2021, a decrease of about 4%[25]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥12,693,749,219.29, an increase of 4.35% from the end of the previous year[3]. - Total assets increased to approximately $12.69 billion, up from $12.17 billion year-over-year, reflecting a growth of about 4.3%[21]. - Total liabilities rose to approximately $3.57 billion, compared to $3.39 billion in the previous year, indicating an increase of about 5.5%[21]. - Non-current assets totaled approximately $8.77 billion, an increase from $8.58 billion, showing a growth of about 2.2%[21]. Cash Flow - The company’s cash flow from operating activities for the year-to-date was ¥273,207,235.15, a decrease of 16.68% compared to the previous year[3]. - Cash flow from operating activities for Q3 2022 was approximately 273.21 million, down from 327.90 million in Q3 2021, a decrease of about 17%[27]. - Cash flow from investment activities showed a net outflow of approximately 400.31 million in Q3 2022, compared to a net outflow of 659.89 million in Q3 2021, improving by about 39%[27]. - The company’s cash and cash equivalents stood at approximately $1.32 billion, slightly down from $1.34 billion[19]. - The cash and cash equivalents at the end of Q3 2022 amounted to approximately 1.10 billion, an increase from 710.12 million at the end of Q3 2021[27]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 52,006[9]. - The largest shareholder, Cheng Xianfeng, holds 40.50% of the shares, totaling 496,526,307 shares, with 66,500,000 shares pledged[9]. - The top ten shareholders hold a total of 124,131,577 unrestricted shares[12]. - Cheng Xianfeng's unrestricted shares amount to 124,131,577, while Hong Kong Central Clearing Limited holds 19,077,392 unrestricted shares[12]. - The company has not identified any other related party relationships among shareholders beyond those disclosed[13]. Government Support and Investments - The company received government subsidies amounting to ¥80,146,605.63 year-to-date, which is an increase of 134.61% compared to the previous year[8]. - Evive Biotech Ltd. plans to issue common stock at $7.2225 per share, with Sino Biopharmaceutical Limited investing $20 million for 2,769,132 shares and committing to invest at least $10 million in future financing[18]. - The total investment from Yifan Pharmaceutical (Hong Kong) Co., Ltd. amounts to $50 million for 6,922,831 shares, bringing the total investment in Evive to $70 million[18]. Operational Changes - The company’s long-term borrowings increased by 40.94% to ¥1,029,599,250.26 due to adjustments in financing structure[7]. - The company reported a 34.12% decrease in operating costs year-to-date, totaling ¥1,331,405,844.19, primarily due to reduced promotional service costs[8]. - The company completed the registration capital change, reducing it from RMB 1,234,106,077 to RMB 1,226,024,827[17]. - The employee stock ownership plan raised RMB 78.5 million, with 70 participants, and purchased 3,960,900 shares at an average price of approximately RMB 10.192 per share[15]. - The company has implemented a stock repurchase plan for restricted stock from 2019, with completion reported on July 29, 2022[14]. Regulatory Approvals - The company’s subsidiary received a drug registration certificate for lactulose oral solution on August 17, 2022[16]. - The company’s subsidiary obtained a registration approval for traditional Chinese medicine from the Singapore Health Sciences Authority in September 2022[16].

Financial Performance - Yifan Pharmaceutical's financial report is guaranteed to be true, accurate, and complete by its management team[2]. - The company's revenue for the first half of 2022 was CNY 1,769,347,695.63, a decrease of 25.58% compared to CNY 2,377,403,852.30 in the same period last year[13]. - Net profit attributable to shareholders for the same period was CNY 160,560,030.39, down 24.67% from CNY 213,141,089.54 year-on-year[13]. - The net profit after deducting non-recurring gains and losses was CNY 105,358,053.27, representing a decline of 42.82% compared to CNY 184,269,117.63 in the previous year[13]. - The net cash flow from operating activities was CNY 183,810,575.85, a decrease of 18.71% from CNY 226,113,089.99 in the same period last year[13]. - Basic earnings per share were CNY 0.13, down 23.53% from CNY 0.17 in the previous year[13]. - Total assets as of June 30, 2022, were CNY 12,475,973,066.21, an increase of 2.56% from CNY 12,165,124,976.56 at the end of the previous year[13]. - Net assets attributable to shareholders were CNY 8,628,473,676.89, up 1.09% from CNY 8,535,174,993.28 at the end of the previous year[13]. - The company reported a total non-operating income of ¥55,201,977.12, primarily due to the write-off of uncollectible amounts during the reporting period[17]. - The company achieved a revenue of CNY 1,769.35 million in the first half of 2022, a decrease of 25.58% compared to the same period last year[36]. Risk Management - The company has not identified any significant risks impacting its operations during the reporting period[2]. - The management highlighted various potential risks including COVID-19, R&D underperformance, and international operational risks[2]. - The company has a comprehensive risk management strategy in place to address various operational challenges[2]. - The company faces risks from the ongoing COVID-19 pandemic, which may adversely affect overseas R&D, production, sales, and supply chain construction[69]. - The company is exposed to risks related to drug development not meeting expectations, including the potential for clinical trial failures and the conversion of capitalized development expenses to operating expenses[70]. - The company is addressing performance volatility risks due to fluctuating prices of key products like Vitamin B5, aiming to enhance pharmaceutical business performance[72]. - The company is adapting to centralized procurement policies that may pressure drug prices and affect domestic sales, while increasing the proportion of international revenue[73]. - The company is closely monitoring exchange rate fluctuations, which have significantly impacted profitability due to mismatched foreign currency assets and liabilities[75]. - The company plans to enhance risk management by optimizing foreign currency allocation and utilizing financial instruments to hedge against exchange rate risks[76]. - International operations are facing risks from geopolitical tensions, particularly the ongoing US-China trade disputes, which may affect revenue and profit from overseas businesses[77]. Research and Development - The company is focused on expanding its market presence and enhancing its product offerings through R&D[2]. - The company is committed to ongoing research and development in the pharmaceutical sector to drive future growth[18]. - The company completed the registration of three products and submitted three new drug applications during the reporting period, with a total of 51 projects still under development[43]. - The company has established partnerships for the sale of certain products, enhancing its market reach and distribution capabilities[19]. - The F-627 product, aimed at treating chemotherapy-induced neutropenia, has received regulatory acceptance in China and is undergoing clinical trials in multiple regions[37]. Market Conditions - The pharmaceutical industry is entering a new phase of high-quality development, driven by innovation and modernization of the industrial chain, but is facing challenges such as declining profits and market growth slowing down[23]. - In the first half of 2022, the pharmaceutical manufacturing industry achieved revenue of CNY 1,400.78 billion, a year-on-year decline of 0.6%, which is 9.7 percentage points lower than the overall level of large-scale industrial enterprises[23]. - The total profit of the pharmaceutical manufacturing industry in the first half of 2022 was approximately CNY 220.95 billion, down 27.6% year-on-year, which is 28.6 percentage points lower than the overall level of large-scale industrial enterprises[23]. - The vitamin industry is experiencing a decline in market conditions due to oversupply, weak terminal consumption growth, and disordered competition among small manufacturers[25]. - The company’s main products, vitamin B5 and its derivatives, are crucial in the vitamin market, which is largely driven by animal nutrition and food additives[26]. Environmental Compliance - The company is committed to adhering to local environmental standards and enhancing safety measures in response to global carbon emission policies[78]. - The company achieved a compliance rate of 100% across all monitored pollutants in the reporting period[87][88]. - The company has implemented effective pollution prevention facilities, ensuring operational compliance with environmental regulations[88]. - The wastewater treatment facility has a processing capacity of 3,000 t/d and has been in operation since November 2002, with stable performance[89]. - The company has established a comprehensive emergency response mechanism for environmental pollution incidents, with multiple drills conducted to enhance emergency handling capabilities[95]. Shareholder Information - Yifan Pharmaceutical reported no cash dividends or stock bonuses for the period[3]. - The company has not reported any significant impairment risks for its overseas assets[53]. - The company has not engaged in any related party transactions during the reporting period[103]. - The company has maintained a clean record with no non-operating fund occupation by major shareholders or related parties[101]. - The total number of ordinary shareholders at the end of the reporting period was 48,451, representing 5% of the total shares[124].